Posted: December 25, 2024 at 2:51 am
Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market
Continue reading here:
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
Posted: December 25, 2024 at 2:51 am
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
See original here:
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Posted: December 25, 2024 at 2:51 am
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Read more here:
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Posted: December 25, 2024 at 2:51 am
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
Read this article:
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis...
Posted: December 25, 2024 at 2:51 am
– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators
Originally posted here:
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
Posted: December 25, 2024 at 2:51 am
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
Here is the original post:
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
Posted: December 25, 2024 at 2:51 am
Findings from recently completed Rheumatoid Arthritis Study raise questions Findings from recently completed Rheumatoid Arthritis Study raise questions
Read more:
XBiotech Pauses Rheumatology program
Posted: December 25, 2024 at 2:51 am
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website.
Visit link:
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Posted: December 25, 2024 at 2:51 am
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the 100th commercial RhodoLED® XL Lamp has now been installed in the US market.
The rest is here:
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
